EGFR and non-small cell lung carcinoma: In the Phase 1/2 KEYNOTE-021 clinical trial, five of seven untreated stage IIIB/IV EGFR-mutant NSCLC patients (71.4%) treated with ICI therapy plus gefitinib had grade 3/4 liver toxicity, leading to permanent treatment discontinuation in four patients [147].